ES3006988T3 - Antitumoral ascorbic acid esters - Google Patents

Antitumoral ascorbic acid esters Download PDF

Info

Publication number
ES3006988T3
ES3006988T3 ES21777302T ES21777302T ES3006988T3 ES 3006988 T3 ES3006988 T3 ES 3006988T3 ES 21777302 T ES21777302 T ES 21777302T ES 21777302 T ES21777302 T ES 21777302T ES 3006988 T3 ES3006988 T3 ES 3006988T3
Authority
ES
Spain
Prior art keywords
compound
mmol
esi
ethyl acetate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21777302T
Other languages
English (en)
Spanish (es)
Inventor
Bargues Teresa Royo
Diop Yagamare Fall
Pacios María Generosa De Los Angeles Gomez
Garcia Hugo Santalla
Fernandez Fatima Garrido
Guido Kurz
Royo María Rubies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suigeneris Farm S L
Original Assignee
Suigeneris Farm S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suigeneris Farm S L filed Critical Suigeneris Farm S L
Application granted granted Critical
Publication of ES3006988T3 publication Critical patent/ES3006988T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES21777302T 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters Active ES3006988T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (1)

Publication Number Publication Date
ES3006988T3 true ES3006988T3 (en) 2025-03-19

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21777302T Active ES3006988T3 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Country Status (10)

Country Link
US (1) US20230278974A1 (https=)
EP (2) EP3967684A1 (https=)
JP (1) JP7805651B2 (https=)
KR (1) KR20230088718A (https=)
CN (1) CN116724028B (https=)
AU (1) AU2021339010A1 (https=)
CA (1) CA3191119A1 (https=)
ES (1) ES3006988T3 (https=)
MX (1) MX2023002970A (https=)
WO (1) WO2022053679A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676461A1 (en) * 2023-03-09 2026-01-14 Mastery Biotech Co., Ltd. Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
CN101550119B (zh) 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP6588764B2 (ja) 2015-01-26 2019-10-09 章博 田井 抗腫瘍剤
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
CA3031979A1 (en) * 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Also Published As

Publication number Publication date
CA3191119A1 (en) 2022-03-17
KR20230088718A (ko) 2023-06-20
JP7805651B2 (ja) 2026-01-26
EP4211123C0 (en) 2024-11-06
JP2023541840A (ja) 2023-10-04
CN116724028B (zh) 2025-07-08
WO2022053679A1 (en) 2022-03-17
US20230278974A1 (en) 2023-09-07
AU2021339010A1 (en) 2023-03-23
EP4211123A1 (en) 2023-07-19
CN116724028A (zh) 2023-09-08
EP4211123B1 (en) 2024-11-06
EP3967684A1 (en) 2022-03-16
MX2023002970A (es) 2023-05-15

Similar Documents

Publication Publication Date Title
ES2731837T3 (es) Profármacos de fumarato de monometilo (MMF)
US7399754B2 (en) N2-quinoline or isoquinoline substituted purine derivatives
US20110237606A1 (en) 3-Deazaneplanocin Derivatives
US20140148400A1 (en) Carbonic anhydrase inhibitors with antimetastatic activity
CN112804995A (zh) 隐杯伞素类似物、其应用及其合成方法
EP2924042A1 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
ES3006988T3 (en) Antitumoral ascorbic acid esters
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
CN102010421A (zh) 青蒿素类衍生物及其应用
CN103965175B (zh) 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用
CN103304573B (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
US20240101584A1 (en) Targeted delivery of 1,2,4,5 tetraoxane compounds and their uses
CN114380864A (zh) 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用
US20160102066A1 (en) Benzothiazole derivative and anti-tumor use thereof
AU2009279400A1 (en) Lipid compounds for supression of tumorigenesis
CN106243130A (zh) 3,6‑二芳基‑[1,2,4]三氮唑并[3,4‑b][1,3,4]噻二嗪类化合物及其用途
US12617805B2 (en) Codrug that disintegrates in intestine, preparation therefor, and use thereof
US20240101585A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
US11400079B2 (en) Antibacterial monobactams
US20230271982A1 (en) Codrug that disintegrates in intestine, preparation therefor, and use thereof
US10093621B2 (en) 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity
WO2025029660A9 (en) Compounds with selectivity for certain cancers
CN116120288A (zh) 一种基于IR780衍生物的hERG钾通道抑制剂及其制备方法与应用
CN102532152A (zh) 4＇-去甲表鬼臼毒素类化合物及其作为抗癌剂的药物用途